MedTrace Logo

GYNecologic Cancer-Related COGnitive Impairment

NCT06662435 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-03-23

No results posted yet for this study

Summary

The goal of this study is to test a home-based and patient-tailored cognitive training intervention among gynecologic cancer patients who have completed chemotherapy and who have experienced cancer-related cognitive impairment.

Conditions

Interventions

BEHAVIORAL

GYNCOG

Participants in the GYNCOG arm will be asked to participate in a home-based cognitive training program utilizing BrainHQ. Participants will be instructed to use the Brain HQ app for approximately 2.5 hours per week. Patients will be provided with a calendar to help keep track of daily BrainHQ use, including the number of exercises completed and the amount of time spent on the app per day. Patients will be asked to undergo the exercises that target the speed and accuracy of information processing. Examples of the exercises include: Double Decision: This exercise tests your ability to quickly identify and choose between two options. Eye for Detail: It challenges participants to spot small differences between two similar images. Participants will be asked to train approximately 30 minutes per BrainHQ session, 5 times per week (i.e., 2.5 hours per week) for 10 weeks, for a total of approximately 25 hours.

Sponsors & Collaborators

Principal Investigators

  • Emma Barber, MD, MS · Northwestern University

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-07
Primary Completion
2025-12-15
Completion
2026-03-20

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06662435 on ClinicalTrials.gov